Imputable.

Previous reporting indicates rates of adverse events with immune checkpoint inhibitors may be overblown. That’s because most patients enrolled in relevant trials (e.g., for refractory metastatic disease) are pretty prone to adverse events at baseline. This Parisian group does a quick tally among 51 recent placebo-controlled trials of anti-cancer agents to determine that more than a quarter of grade 3+ toxicities attributed to anti-cancer drugs also occur in the placebo arm. | Moreau-Bachelard, N Engl J Med 2019